Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Jaguar Animal Health Business Overview & Revenue Model
Jaguar Animal Health Earnings Call Summary
Jaguar Animal Health Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 11.51M | 11.69M | 9.76M | 11.96M | 4.33M | 9.38M | Gross Profit |
| 9.47M | 9.73M | 7.72M | 9.94M | 2.00M | 6.11M | EBIT |
| -32.04M | -30.83M | -34.29M | -34.41M | -39.07M | -21.30M | EBITDA |
| -38.48M | -36.66M | -33.13M | -33.38M | -42.35M | -28.74M | Net Income Common Stockholders |
| -39.73M | -38.49M | -41.30M | -47.45M | -60.25M | -36.79M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.69M | 8.00M | 6.47M | 5.47M | 17.05M | 8.09M | Total Assets |
| 51.46M | 53.42M | 50.76M | 47.45M | 53.27M | 42.84M | Total Debt |
| 38.34M | 36.53M | 37.09M | 34.84M | 29.36M | 16.21M | Net Debt |
| 32.65M | 28.52M | 30.63M | 29.37M | 12.31M | 8.12M | Total Liabilities |
| 48.15M | 46.93M | 45.87M | 48.81M | 41.41M | 25.64M | Stockholders Equity |
| 830.00K | 7.29M | 4.96M | -657.00K | 11.61M | 17.20M |
| Cash Flow | Free Cash Flow | ||||
| -29.87M | -29.61M | -33.24M | -34.78M | -34.98M | -15.29M | Operating Cash Flow |
| -29.65M | -29.38M | -33.24M | -33.10M | -34.97M | -15.28M | Investing Cash Flow |
| -231.00K | -231.00K | 0.00 | -1.68M | -6.00K | -7.00K | Financing Cash Flow |
| 23.90M | 31.20M | 34.23M | 23.18M | 43.94M | 19.49M |
Jaguar Animal Health Technical Analysis
Jaguar Animal Health Risk Analysis
Jaguar Animal Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
41 Neutral | $4.57M | ― | -423.79% | ― | 19.75% | 95.65% | |
34 Underperform | $3.99M | ― | -105.70% | ― | -100.00% | 28.48% | |
| $5.37M | ― | -221.23% | ― | ― | ― | ||
| $7.48M | ― | ― | ― | ― | |||
| $3.31M | ― | -79.71% | ― | ― | ― | ||
46 Neutral | $4.63M | ― | -163.47% | ― | -100.00% | 78.91% |
Jaguar Animal Health Corporate Events
On April 30, 2025, Jaguar Health announced promising initial results from a proof-of-concept trial of crofelemer, a novel liquid formulation aimed at reducing the need for total parenteral nutrition (TPN) in patients with microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The trial demonstrated that crofelemer reduced TPN requirements by up to 27% and 12.5% for MVID and SBS-IF patients, respectively, and showed potential for improving nutrient absorption and quality of life. These findings may support crofelemer’s inclusion in expedited regulatory programs in the EU and US, highlighting its potential as a novel therapeutic option for these rare conditions.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s stock score is notably low, primarily due to substantial financial challenges, including high leverage and negative profitability. Technical analysis indicates bearish trends, while valuation metrics are unappealing. Although earnings calls and corporate events offer some optimism with revenue growth and potential regulatory advancements, persistent net losses and clinical trial challenges continue to weigh heavily on the stock’s potential.
To see Spark’s full report on JAGX stock, click here.
On April 28, 2025, Jaguar Health announced an investor webcast scheduled for April 30, 2025, to discuss preliminary results from a proof-of-concept trial of crofelemer for treating rare diseases like microvillus inclusion disease and short bowel syndrome with intestinal failure. The webcast will cover patient experiences, the drug’s impact on disease progression, and potential regulatory pathways, highlighting Jaguar’s commitment to addressing unmet clinical needs and its strategic positioning in the pharmaceutical industry.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Underperform.
Jaguar Animal Health’s overall stock score is low primarily due to substantial financial challenges, including high leverage and negative profitability. Technical analysis suggests bearish trends, and valuation metrics are unappealing. While recent earnings calls and corporate events provide some optimism with revenue growth and potential regulatory advancements, ongoing net losses and clinical trial challenges continue to weigh heavily on the stock’s potential.
To see Spark’s full report on JAGX stock, click here.
Jaguar Health announced its participation in the 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi, where they will present proof-of-concept data for their products, including crofelemer. The company is actively pursuing business development opportunities and regulatory designations in the U.S. and Europe, aiming to expand the market reach of crofelemer for various indications, which could significantly impact their market positioning and stakeholder interests.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health is currently facing substantial financial difficulties with high leverage and negative profitability, as reflected in the financial performance and valuation scores. Technical analysis suggests bearish trends, while recent earnings calls and corporate events provide some optimism with revenue growth and potential regulatory advancements. However, the company’s ongoing net losses and challenges in clinical trials continue to weigh on its overall stock score.
To see Spark’s full report on JAGX stock, click here.
On March 31, 2025, Jaguar Health closed a private placement, raising approximately $3.448 million through convertible promissory notes and warrants. The funds will be used for working capital and general corporate purposes, with expectations of key catalysts in the second quarter of 2025 related to crofelemer development for rare diseases and cancer therapy-related diarrhea, potentially enhancing the company’s value.
Jaguar Health, Inc. announced a reverse stock split of its common stock at a 1-for-25 ratio, effective March 24, 2025, to comply with Nasdaq listing standards and attract institutional investors. The reverse stock split will reduce the number of shares and increase the share price, with no fractional shares issued; stockholders will receive cash for any fractional shares. The company’s stock will continue trading on Nasdaq under the symbol ‘JAGX’ with a new CUSIP number.
On March 13, 2025, Jaguar Health held a special meeting where stockholders approved two proposals, including a reverse stock split of the company’s common stock. The company is advancing its plant-based drug, crofelemer, for rare diseases and cancer therapy-related diarrhea, with expected trial results and regulatory discussions in 2025. These developments could enhance Jaguar’s market positioning and offer new treatment pathways, potentially benefiting stakeholders.